Abstract We use 1,2-diacetylbenzene (1,2-DAB) to probe molecular mechanisms of proximal giant neurofilamentous axonopathy (PGNA), a pathological hallmark of amyotrophic lateral sclerosis. The spinal cord proteome of rodents displaying 1,2-DAB PGNA suggests a reduction in the abundance of α-II spectrin (Spna2), a key protein in the maintenance of axonal integrity. Protein immunoblotting indicates that this reduction is due to Spna2 degradation. We investigated the importance of such degradation in 1,2-DAB PGNA. Spna2 mutant mice lacking a calpain-and/or caspase-sensitive domain (CSD), thus hypothetically resistant to 1,2-DAB, and wild-type littermates, were treated with 1,2-DAB, 35 mg/kg/day, or saline control, for 3 weeks. 1,2-DAB induced motor weakness and PGNA, irrespective of the genotype. Spna2-calpain breakdown products were not detected in mutant mice, which displayed a normal structure of the nervous system under saline treatment. Intriguingly, treatment with 1,2-DAB reduced the abundance of the caspase-specific 120-kDa Spna2 breakdown products. Our findings indicate that degradation of Spna2 by calpain-and/or caspase is not central to the pathogenesis of 1,2-DAB axonopathy. In addition, the Spna2-CSD seems to be not required for the maintenance of the cytoskeleton integrity. Our conceptual framework offers opportunities to study the role of calpain-caspase cross talk, including that of the protease degradomics, in models of axonal degeneration. Kassa R. and Monterroso V. have equally contributed to the study.
Introduction
Proximal giant neurofilamentous axonopathy (PGNA) is an early pathological hallmark of a host of neurodegenerative diseases, including the amyotrophic lateral sclerosis, of which the pathogenetic mechanisms remained unclear. Giant axons filled with 10-nm neurofilaments (NF) mostly develop at proximal sites of elongated motor axons (Delisle and Carpenter 1984; Hirano et al. 1984; Okamoto et al. 1990; Al-Chalabi and Miller 2003) . These sites are enriched with the structural protein α-II spectrin (Spna2), reportedly critical for the neurobiology of axon pathfinding, neuronal plasticity, and maintenance of the cytoskeleton integrity through cycles of calpain-and caspase-mediated proteolysis (Simonovic et al. 2006; Meary et al. 2007 ). The role of such physiological process in response to neurodegenerative stimuli has yet to be elucidated.
We use 1,2-diacetylbenzene (1,2-DAB), a γ-diketonelike neuroprotein reactant, as probe to study molecular mechanisms associated with PGNA (Tshala- Katumbay et al. 2005 Katumbay et al. , 2008 Katumbay et al. , 2009 . Two-dimensional differential in-gel electrophoresis (2D-DIGE) in combination with matrixassisted laser desorption time-of-flight tandem mass spectrometry (MALDI-TOF/MS-MS) have shown that Spna2 was a target of 2,5-hexanedione (2,5-HD), the neurotoxic aliphatic cousin of 1,2-DAB (Tshala- Katumbay et al. 2009; Spencer et al. 2002) . Protein immunoblots of tissues from animals treated with the aforementioned neurotoxic compounds, at doses that induce comparable neuromuscular weakness (Conference proceedings, ninth meeting of the International Neurotoxicology Association, Germany, 2003) , showed that Spna2 was cleaved through a proteolytic pattern consistent with the activation of calpains and/or caspases (Meary et al. 2007 ). Both γ-diketones look-alike 1,2-DAB and 2,5-HD crosslink neuroproteins and induce axonal damage by mechanisms that have yet to be elucidated (Spencer et al. 2002) . In this study, we asked whether the proteolysis, mainly calpain-and/or caspase-mediated, of Spna2 was central to the development of the PGNA seen in animals treated with the 1,2-DAB. Mutant Spna2 tm1.1Gnic mice that lack a domain sensitive to proteases calpains and/ or caspases (CSD) of Spna2, but possibly sensitive to yet not elucidated caspase-proteolytic mechanisms (Wang 2000; Warren et al. 2005; Meary et al. 2007) , and their wild-type (WT) littermates were treated with 1,2-DAB, 35 mg/kg/day, or equivalent amount of 1,2-DAB-vehicle control, 5 days a week, for 3 weeks.
Control Spna2 tm1.1Gnic mice and their WT littermates displayed a normal phenotype and structure of peripheral nerves. However, those treated with 1,2-DAB displayed motor weakness and intraspinal 10 nm NF-filled axonal swellings. Intriguingly, calpain-and caspase-specific proteolytic mechanisms (associated with the 120-kDa breakdown product of Spna2) showed a differential pattern of susceptibility to 1,2-DAB; a pattern that was seen in animals with end-stage severe motor weakness. These findings indicate that degradation of Spna2 by calpains and/or caspases may not be central to the pathogenesis of 1,2-DAB-induced PGNA. In addition, they suggest that the CSD of Spna2 may not be relevant for the maintenance of the cytoskeleton integrity in peripheral nerves. Our experimental framework offers opportunities for studies that may further elucidate the role of calpain-caspase cross talk, including that of the protease degradomics, in models of axonal degeneration (Zhao et al. 1999; Wang 2000; Neumar et al. 2002; Overall et al. 2004; Warren et al. 2005 Warren et al. , 2007 .
Materials and Methods

Chemicals
1,2-DAB (99%) was purchased from Aldrich Chemical Co. (Madison, WI, USA) and desiccated at room temperature. The stock sample was checked by gas chromatographymass spectrometry to confirm the purity of the chemical.
Animals Heterozygous Spna2
tm1.1Gnic mice backcrossed nine times on C57BL/6 background were kindly provided by Dr. Nicolas, INSERM (Institut National de la Santé et de la Recherche Médicale, France). In these mice, the three exons in Spna2 encoding the calmodulin-binding domain, and the caspase-and calpain-cleavage sites, were deleted using a classical knockout approach while keeping the rest of the encoded mutant Spna2 intact so as not to impair the translation reading frame (Meary et al. 2007) . A mutant colony was established in our institute (Department of Comparative Medicine) by interbreeding heterozygous mice. Animals, including the WT littermates of Spna2 mutants, were kept on 12/12-h light dark cycle, and food and water were given ad libitum. Studies were conducted in accordance with the institutional (OHSU) guidelines for the care and use of laboratory animals.
Genotyping
Two 5-mm long tail biopsy specimens were taken from 14 to 21-day-old mice for genotyping. To extract DNA, tail biopsies were digested overnight at 55°C in 200 μl of 1 mg/ml proteinase K in 100 mM Tris (pH 8.5), 5 mM EDTA, and 200 mM NaCl buffer. Afterwards, digested samples were boiled for 15 min to inactivate proteinase K and then ethanol precipitation of DNA. Genomic DNA (1-2 μl) was used in a 25-μl multiplex polymerase chain reaction (PCR) that included the following primers: primer 1, forward 5′-gatctgaaagccaatgagtctcggc-3′; primer 2, forward 5′-tacatagagaatggccagtcttttgac-3′; and primer 3, reverse 5′-gcacaactgggtaaggtaaggttcctattcc-3′. The PCR mix consisted of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2 mM MgCl 2 , 0.2 mM dNTPs, 0.18 mM primers 1-3, and 0.5 unit Taq polymerase (Invitrogen, Carlsbad, CA, USA). After an initial denaturation at 94°C for 4 min, 35 cycles of 20 s at 94°C, 20 s at 65°C, and 30 s at 72°C were carried out followed by a final elongation at 72°C for 5 min. PCR products were separated by electrophoresis through a 2% agarose gel containing SYBR safe (Invitrogen, Carlsbad, CA, USA). The WT Spna2 allele amplified a single 201-bp amplicon with primers 2+3. The mutant Spna2 allele amplified single 374-bp amplicon with primers 1+3. Heterozygous animals showed both 201 and 374-bp amplicons. Regular genotyping of new progeny for our heterozygousbased breeding colony revealed animals with expected genotypes, with amplicon bands corresponding to the expected lengths of Spna2.
Animal Treatment, Observation, and Motor Tests
Young adult male mice (homozygous Spna2 tm1.1Gnic or their WT littermates, n010 per genotype) were treated intraperitoneally with 1,2-DAB at a dose of 35 mg/kg body weight/ day (n07/genotype/studies 1 and 2) or equivalent amount of vehicle (2% acetone in 0.9% saline; n03-4/genotype/studies 1 and 2), once daily, 5 days a week, for 3 weeks. This dosing schedule was previously used to develop the mouse model for 1,2-DAB axonopathy (Tshala-Katumbay et al. 2005) and conduct preliminary studies in the Spna2 mutant (study 1) prior to the formal experiment (study 2). During both studies, injection sites were rotated around the abdomen and care was taken to minimize leakage and discomfort.
Animals were weighed daily to check for changes in body weight and adjustment of the 1,2-DAB dose. They were also examined daily for the presence of the hindlimb extension reflex, elicited when the animal is gently raised by the tail. In addition, mice were assessed for deficits in motor coordination using a software-driven rotarod apparatus (AccuScan Instruments, Inc., Columbus, OH, USA). Animals were placed on a rotating rod (70-mm diameter) in a constant mode set at 7 rpm. The apparatus had an automatic fall detection system comprising photobeams. Animals were tested three times a week with two consecutive trials per session and a cutoff point of 180 s. The latency to fall was measured during each trial.
Animal Perfusion and Tissue Processing Protocols
At study termination, animals that have developed severe motor weakness were deeply anesthetized with 4% isofluorane (1 l oxygen/min). Those retained for biochemical studies were transcardially perfused with 0.01 M phosphatebuffered saline (PBS, pH 7.4) to remove the blood. Immediately thereafter, the spinal cord was removed by pressurized saline extrusion. Lumbosacral spinal cord segments were flash-frozen in liquid nitrogen and stored at −80°C for Western blotting studies.
For ultrastructural studies, animals were transcardially perfused with PBS followed by 4% paraformaldehyde and 5% glutaraldehyde in 0.1-M sodium cacodylate buffer (pH 7.4). The lumbosacral segment of the spinal cord and the proximal sciatic nerves from both sides were dissected out, postfixed in 1% osmium tetraoxide in PBS, dehydrated and embedded in epoxy resin. Cross sections (~900 nm) of fixed tissue were stained with 1% toluidine blue and screened by bright field microscopy. Thin sections (~90 nm) of regions of interest were stained with 2% uranyl acetate followed by 1% lead citrate and examined by transmission electron microscopy (TEM).
Western Blotting
Spinal cord tissues were subjected to direct ultrasonic shearing in 2× sodium dodecyl sulfate polyacrylamide gel electrophoresis sample loading buffer, followed by heat denaturation at 95°C for 5 min. One hundred micrograms of wet tissue was homogenized in 0.1 ml of buffer/mg. Tissue lysates were stored at −70°C until later use for protein immunoblotting as previously described (BanaySchwartz et al. 1992 ). Proteins were resolved by 7.5% sodium dodecyl sulfate polyacrylamide gels and transferred overnight to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). Loading variations were ruled out after protein immunoblots using the glucosidase-2β (Gl-IIβ) antibody (Santa Cruz Biotechnology, CA, USA). Membranes were incubated with 10% dry milk in Tris-buffered saline containing 0.3% Tween-20 (TBST) for 0.5 h to block nonspecific binding and immunoprobed for 1 h at room temperature with the mouse monoclonal antibody to Spna2 (clone AA6 from Enzo Life Sciences, Plymouth Meeting, PA, USA; dilution 1:1,000 in 5% dry milk/TBST). After incubation with a goat anti-mouse horseradish peroxidaseconjugated antibody (Santa Cruz Biotechnology; 1:2,000 in 5% dry milk/TBST), peroxidase activity was detected with an enhanced chemiluminescent detection system (DuPont NEN Research Products, Boston, MA, USA) following the manufacturer's instructions.
Statistical Analysis
A linear contrast was computed for each animal's weekly series of body weight measurements, resulting in three contrasts per animal, with each contrast interpretable as the average change in body weight per day. The collection of three contrasts was then analyzed using multivariate analysis of variance to determine whether the daily average change in body weight was influenced by treatment, genotype, or the interaction between these factors.
The mean latency to fall from the rotarod for each genotype and treatment-based group (i.e., WT vehicle, WT 1,2-DAB, mutant vehicle, and mutant 1,2-DAB) was computed for each rotarod session, resulting in three mean values per week. The between group difference in these values (mean latency to fall from rotarod/day/group) for each week was then analyzed with two-way analysis of variance (ANOVA).
Densitometric analysis of the Gl-IIβ-standardized intensity of bands corresponding to 280 (mutant) or 285 (WT) full-length Spna2, or 150-and 120-kDa spectrin breakdown products (SBDP), was done on digitized Western blot images using the Image J software from the National Institute of Health (NIH). The between group difference in the mean gray values of the 280/285-kDa bands and ratio of the mean gray values of 120-kDa SBDP bands vs. their corresponding 280-or 285-kDa bands was evaluated with two-way ANOVA; and the ratio of the mean gray values of the 150-vs. 285-kDa bands analyzed with one-way ANOVA. Differences were considered statistically significant at p<0.05.
Results
Body Weight, Motor Signs, and Rotarod Performance
Vehicle-injected WT and mutant mice showed no significant changes in body weight. 1,2-DAB-treated animals lost an average of 0.44 g/day (95% confidence interval (CI), 0.31-0.58 g/day) during the first week regardless of the genotype. During the second and third week, the loss in body weight averaged to 0.82 g/day (95% CI, 0.71-0.92 g/day). Neither the Spna2 mutant mice nor the WT mice injected with vehicle showed abnormalities in locomotion and performed equally well on the rotarod apparatus. Animals treated with 1,2-DAB exhibited gait abnormalities after the first week of treatment. Similar motor deficits were seen in the Spna2 mutant mice. Both genotypes showed a hunchback posture, a broad-based gait, and dragged all four limbs by the end of the study. In addition, a progressive decrease in latency to fall from the rotating rod was found in 1,2-DAB-treated animals from the second week onwards compared to the vehicle-injected, and genotype did not modify the effect of 1,2-DAB on rotarod performance (mean latency to fall/ treatment group±standard error of the mean, 180±14 s for vehicle-treated animals vs. 112±19 s for 1,2-DAB-treated animals during week 2, p<0.05; or 180±14 s vs. 67±14 s for vehicle-vs. 1,2-DAB-treated animals, respectively, during week 3, p<0.0001). Fig. 1 a Left lanes, Spna2 immunoblots performed on spinal cord lysates from WT animals treated with vehicle or 1,2-DAB. The expression of the 150-kDa SBDP (Spna2 breakdown product) was increased in animals treated with 1,2-DAB. In contrast, the expression of the caspase-specific 120-kDa SBDP seems to be decreased in animals treated with 1,2-DAB. Right lanes, immunoblots for Spna2 mutant mice. Note the absence of the 150-kDa SBDP. A baseline expression of the 120-kDa SBDP in the vehicle-treated mice possibly occurs through a secondary Spna2 site for caspase-mediated proteolysis (Meary et al. 2007 ). Gl-IIβ, loading control. b Densitometric evaluation of the immunosignal intensity of bands revealed a significant increase in the abundance (mean gray value±SD) of the 150-kDa SBDP relative to that of the full-length 285-kDa Spna2 ( ** p<0.005). c Densitometric findings revealed a significant reduction in the abundance (mean gray value±SD) of the 120-kDa SBDP relative to that of the full-length Spna2 in both genotypes after treatment with 1,2-DAB ( * p<0.05)
Western Blotting
We performed a Western blotting analysis of spinal cord homogenates to determine the effect of 1,2-DAB treatment on Spna2 cleavage in mutants compared to WT mice. After controlling for loading variations, no statistical difference in the immunosignal intensity of the full-length bands was detected in 1,2-DAB-treated animals compared to vehicleinjected controls across the genotypes. Our statistical analyzes were conducted using means and/or ratios of densitometric values within genotypes. As expected, in Spna2 mutant mice, the 150-kDa SBDP were not detected. However, a significant increase in the mean relative abundance of this breakdown product was found in 1,2-DAB-treated WT animals compared to vehicle-injected WT (p<0.005). A significant reduction in the relative abundance of the 120-kDa caspase-specific SBDP was found in 1,2-DAB-treated mice compared to vehicle-injected respective controls irrespective of the genotype (p<0.05; Fig. 1 ).
Neuropathology
WT and mutant mice treated with vehicle retained a normal morphology of the spinal cord and proximal sciatic nerves. However, those treated with 1,2-DAB showed a bluish discoloration of tissues and TEM structural abnormalities in the nervous system. In agreement with findings from motor assessment, no differences were detected in the neuropathological features induced by 1,2-DAB in Spna2 mice relative to WT animals. In both genotypes, examination of toluidine bluestained lumbar spinal cord sections from both WT and Spna2 mutant mice treated with 1,2-DAB showed enlarged 10 nm NF-filled axons in lumbar anterior horns (Figs. 2 and 3) .
Ultrastructural studies of the intraspinal swollen axons of 1,2-DAB-treated animals revealed axons densely packed with maloriented 10-nm NF, irrespective of the genotype. TEM of the proximal sciatic nerves showed similar findings in addition to a clustering of microtubules and organelles (mitochondria) in both wild-type (Fig. 4) and mutant mice (Fig. 5) .
Discussion
We report for the first time neuropathological changes induced by axonopathic 1,2-DAB in mutant mice genetically engineered to resist calpain and caspase cleavage of Spna2 (Meary et al. 2007 ). 1,2-DAB induces a bluish discoloration of nervous system tissues, motor weakness, and a PGNA in elongated motor axons, irrespective of the mouse genotype. These findings remain consistent with those previously done in rodents treated with 1,2-BAB (Kim et al. 2001; Spencer et al. 2002; Tshala-Katumbay et al. 2005) . As expected, the 150-kDa breakdown products of Spna2 were not detected in mutant mice, which still displayed a normal phenotype and structure of peripheral sciatic nerves with and without vehicle treatment. Intriguingly, treatment with 1,2-DAB reduced Fig. 2 Cross sections of ventral horns in lumbar spinal cords from vehicle-(a) and 1,2-DAB wild-type-treated animals (b). Giant axonal swellings (asterisk) were seen in lumbar anterior horns. Arrows normal axons. Arrowheads cell bodies. BV blood vessel. Scale bar 200 μm Fig. 3 Micrographs from Spna2 mutants treated with vehicle (a) or 1,2-DAB (b). The anterior horns of these animals displayed a pathology similar to that seen in wild-type animals. Giant axonal swellings (asterisk) were also seen in these animals, following treatment with 1,2-DAB. Arrows normal axons. Arrowheads cell bodies. BV blood vessel. Scale bar 200 μm the expression of the 120-kDa caspase-specific SBDP even in the wild-type mice.
Changes in the expression of Spna2, including its proteolytic cleavage, have been linked to both normal physiological processes (Lynch and Baudry 1987; Sikorski et al. 2000; Czogalla and Sikorksi 2005; Susuki and Rasband 2008) and neurological insults including those associated with neurodegeneration (Nath et al. 1996; Zhao et al. 1999; Pike et al. 2001; Siman et al. 2004; Warren et al. 2005 Warren et al. , 2007 Indraswari et al. 2009 ) or axonal disease induced by γ-diketone-like compounds including 2,5-hexadione (Genter St Clair et al. 1988; Tshala-Katumbay et al. 2008 ). However, the role of Spna2-specific domains, notably its CSD domain, has not been elucidated in relation to the integrity of the cytoskeleton in peripheral nerves. Our study suggests that the Spna2 CSD domain may not be relevant for the maintenance of the cytoskeleton integrity both in normal and Spna2 tm1.1Gnic mutant mice. These findings appear to be consistent with previous reports that suggest that the CSD mutation in the Spna2 tm1.1Gnic mice affects only the fragility of Spna2 to proteases and not its ability to be incorporated into the membrane skeleton (Meary et al. 2007 ). The genetic deletion of the CSD of Spna2 does not protect against the axonopathic effects of 1,2-DAB suggesting that the cleavage of Spna2 may be a downstream event in the pathogenesis of 1,2-DAB axonopathy. In this later event, protein adduction, crosslinkings, and polymerization have been proposed as primary pathogenetic events, as similarly hypothesized for 2,5-HDinduced axonopathy (DeCaprio 1987; DeCaprio et al. 1987; Spencer et al. 2002; LoPachin and DeCaprio 2005) . The extent to which cellular mechanisms of proteolysis may be involved has, however, yet to be elucidated (Tshala-Katumbay et al. 2008 ).
The increased abundance of the putatively 150-kDa calpain-specific SBDP relative to those specific to caspase Fig. 4 Transmission electron micrographs of sciatic nerves from vehicle-(a) or 1,2-DABtreated wild-type mice. Densely packed axons and clustering of organelles and microtubules (circles) were seen in animals treated with 1,2-DAB (b) relative to vehicle-treated ones (a). Scale bar 500 nm Densely packed axons and clustering of organelles and microtubules (circles) were seen in 1,2-DAB-treated animals (b) relative to vehicletreated ones (a). Scale bar 500 nm cleavage of Spna2, i.e., the 120-kDa SBDP, raises interesting questions. The increase of 150-kDa SBDP in WT mice treated with 1,2-DAB, with no decrease in the abundance of the full-length native Spna2, may possibly be explained by an increased de novo synthesis of Spna2 in reaction to the axonopathic stress induced by 1,2-DAB. This proposal is consistent with previous findings that showed an increase in the expression of Spna2 in models neurodegeneration, some of which may be associated with proteolytic breakdown of Spna2 (Siman et al. 2004; Indraswari et al. 2009 ). This proposal underscores, however, the nonquantitative value of proteomic methodologies such as those we previously used to estimate changes in the expression of Spna2 following animal intoxication with axonopathic γ-diketones (Tshala- Katumbay et al. 2008 Katumbay et al. , 2009 .
The presence of 120-kDa caspase SBDP in WT mice is consistent with the earlier proposal that suggests the existence of secondary sites for caspase cleavage of Spna2 (Meary et al. 2007 ). However, the decrease in their abundance following treatment with 1,2-DAB is intriguing. It is possible that caspases or their related aforementioned low molecular weight SBDP fragments have higher affinity for the neuroprotein crosslinking agent 1,2-DAB and hence, become adducted by 1,2-DAB and subsequently directed towards other proteolytic systems, or, for caspases, inactivated in their functions after adduction by 1,2-DAB.
Our study has shown that the CSD of Spna2 may not be relevant for the maintenance of the cytoskeleton integrity in peripheral nerves. In addition, genetic deletion of the CSD of Spna2 is not protective against the deleterious effects of axonopathic 1,2-DAB. However, the possible differential susceptibility of calpain-vs. caspase-related proteolytic mechanisms (associated with the 120-kDa SBDP) to the axonopathic 1,2-DAB demonstrates the usefulness of our model for studies aimed at elucidating to the role of calpaincaspase cross talk, including that of the protease degradomics, in models of axonal degeneration (Zhao et al. 1999; Wang 2000; Neumar et al. 2002; Overall et al. 2004; Warren et al. 2005 Warren et al. , 2007 . This proposal, however, bears some limitations as the 145-kDa calpain-specific SBDP were not readily identifiable during our experimentations (Zhang et al. 2003; Liu et al. 2006) .
